SANION.ST - Saniona AB (publ)

Stockholm - Stockholm Real Time Price. Currency in SEK
22.50
+1.10 (+5.14%)
At close: 5:29PM CEST
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close21.40
Open21.55
Bid22.40 x 0
Ask22.50 x 0
Day's Range21.55 - 23.00
52 Week Range15.00 - 32.95
Volume57,221
Avg. Volume95,594
Market Cap661.781M
Beta (5Y Monthly)1.35
PE Ratio (TTM)N/A
EPS (TTM)-2.95
Earnings DateMay 07, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est77.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Notice of annual shareholders’ meeting in Saniona AB

      The shareholders in Saniona AB, Reg. No. 556962-5345, are hereby invited to attend the annual shareholders’ meeting (Sw. As a precautionary measure to reduce the risk of spreading the coronavirus, the board of directors of Saniona AB (“Saniona”) has decided to keep planned speeches at the shareholders’ meeting to a minimum and that no refreshments will be served. Participation at the shareholders’ meeting by members of the board of directors and management as well as the number of non-shareholders present at the shareholders’ meeting will be limited in an effort to keep the shareholders’ meeting brief and efficient, and thereby minimizing the risk of spreading the coronavirus.

    • GlobeNewswire

      Saniona changes date for Annual General Meeting and updates financial calendar

      PRESS RELEASE March 31, 2020   Saniona AB (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that the board of directors.

    • GlobeNewswire

      Saniona enters into second collaboration agreement with Boehringer Ingelheim in schizophrenia

      Saniona (SANION.ST), a clinical stage biopharmaceutical company focused on rare diseases of the central nervous system, today announced a new research collaboration with Boehringer Ingelheim in schizophrenia. Saniona may receive up to €76.5 million in milestone payments as well as royalties on worldwide net sales of resulting products under the collaboration.

    • GlobeNewswire

      Saniona Announces Management Transition to Support Strategic Transformation

      Saniona (SANION.ST), a clinical stage biopharmaceutical company focused on rare diseases of the central nervous system, today announced the appointment of Anita Milland as interim Chief Financial Officer and Head of Investor Relations effective immediately following the departure of Saniona Chief Financial Officer and co-founder Thomas Feldthus. As part of Saniona’s strategic transformation and expansion in the US, Jorgen Drejer, Ph.D., Chief Scientific Officer and co-founder will assume the role of Deputy Chief Executive Officer, which was previously held by Mr. Feldthus.

    • GlobeNewswire

      Saniona completes its six months double blind Phase 2a trial of Tesomet in hypothalamic obesity

      Saniona (SANION.ST), a clinical stage biopharmaceutical company focused on rare diseases of the central nervous system, today announces the last patient has completed the last visit in the six-month, placebo-controlled section of a Phase 2a study of Tesomet in hypothalamic obesity (HO). A total of 18 patients, of the original 21 who started the trial, have now continued into the open-label extension part of the study. The placebo-controlled part of the study remains on track to report top-line results in Q2 2020.

    • GlobeNewswire

      Saniona’s announces last day of trading in BTU and first day of trading in warrants of series TO 1, TO 2 and TO 3

      Saniona AB's rights issue of units has been registered with the Swedish Companies Registration Office. Euroclear's record date for conversion from BTU to warrants is March 19th, 2020. The new warrants are expected to be distributed to the respective shareholder’s VP account/depot on March 23rd, 2020.

    • GlobeNewswire

      Saniona’s rights issue of free-of-payment units is oversubscribed

      On March 2, 2020 Saniona AB´s rights issue of free-of-payment units, consisting of 3,042,672 warrants of three separate series (TO 1, TO 2, TO 3) has ended. The rights issue was oversubscribed and approximately 95,77 percent of the rights issue was subscribed for by exercise of unit rights (subscription rights for units allotted to shareholders).A total of 1,014,224 units are issued through the rights issue consisting of 1,014,224 warrants of series TO 1, 1,014,224 warrants of series TO 2 and 1,014,224 warrants of series TO 3.

    • GlobeNewswire

      Saniona publishes supplementary prospectus

      NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. Saniona AB (publ) (”Saniona”) has prepared a supplementary prospectus, in addition to the prospectus relating to Saniona’s current rights issue of units, which was published on February 14, 2020 and which has been approved and registered by the Swedish Financial Supervisory Authority. The supplementary prospectus is available on Sanionas website www.saniona.com/se and on Sedermera Fondkommissions website www.sedermera.se.

    • GlobeNewswire

      Saniona announces Chief Financial Officer Thomas Feldthus will be departing the company

      Saniona (SANION.ST), a clinical stage biotech company focused on rare diseases of the Central Nervous System, today announces that co-founder and Chief Financial Officer Thomas Feldthus will be leaving the company. As part of its strategic transformation Saniona has initiated the search for a new CFO, who will be based in the U.S. along with CEO Rami Levin. Thomas Feldthus, who is one of the co-founders of Saniona, will continue as CFO for an interim period to ensure a smooth transition and transfer of responsibilities to the new CFO.

    • GlobeNewswire

      Correction regarding ISIN code for BTU in prospectus

      PRESS RELEASE February 14, 2020                                                      In the prospectus, that was made public today, regarding Saniona AB's (publ) rights.

    • GlobeNewswire

      Saniona publishes prospectus relating to the rights issue of units

      The prospectus relating to the rights issue of units that Saniona AB (“Saniona or the Company”) announced on January 10, 2020 has today been approved and registered by the Swedish Financial Supervisory Authority and is now available on Saniona’s website, www.saniona.com, together with other information related to the rights issue. The prospectus will also be available on Sedermera Fondkommissions website, www.sedermera.se and on the Swedish Financial Supervisory Authority website, www.fi.se. The subscription period for the rights issue commences on Monday, 17 February 2020 and proceeds up to and including 2 March 2020.

    • GlobeNewswire

      Bulletin from the extraordinary general meeting on February 7, 2020 in Saniona AB

      Today, on February 7, 2020, an extraordinary general meeting was held in Saniona AB. The extraordinary general meeting resolved to approve the board of directors’ resolution of January 10, 2020, on a directed issue of a maximum of 465,518 units consisting of warrants. With deviation from the shareholders' preferential rights, the units may only be subscribed for by Formue Nord Fokus A/S and Formue Nord Markedsneutral A/S, whereby 102,414 units shall be subscribed for by Formue Nord Fokus A/S and 363,104 units shall be subscribed for by Formue Nord Markedsneutral A/S. The reason for the deviation from the shareholders' preferential rights is that the warrants are issued as part of the financing structure which was published by the company on January 10, 2020.

    • GlobeNewswire

      Saniona publishes its year-end report for 2019

      PRESS RELEASE February 7, 2020 Financial highlights Jan – Dec 2019 (Jan – Dec 2018) Net revenues were SEK 2.7 M (54.9 M)EBIT was SEK -103.9 M (-54.2 M)Net profit/loss was.

    • GlobeNewswire

      Change in number of shares and votes in Saniona AB (publ)

      During January, the registered number of shares and votes in Saniona AB (publ) (“Saniona”) has increased due to the directed issue of shares resolved by the board of directors on January 10, 2020. This information is such information as Saniona AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The Company has five programs in clinical development.

    • GlobeNewswire

      Notice of extraordinary general meeting in Saniona AB

      The shareholders in Saniona AB, Reg. No. 556962-5345, are hereby invited to attend the extraordinary general meeting (Sw. Such temporary re-registration of ownership must be implemented no later than as of Saturday 1 February 2020.

    • GlobeNewswire

      Saniona completes private placement of SEK 25 million and proposes financing of up to SEK 158 million

      PRESS RELEASE NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH.

    • GlobeNewswire

      Saniona appoints CNS & rare disease veteran Rami Levin as President and Chief Executive Officer

      Saniona (SANION.ST), a clinical stage biotech company focused on rare diseases relating to eating disorders and the central nervous system (CNS), today announces that it has appointed the highly experienced pharmaceutical industry executive Rami Levin as Chief Executive Officer to oversee its transition to a fully-fledged biopharmaceutical company with focus on rare diseases.

    • GlobeNewswire

      Saniona’s partner Medix submits new drug application in Mexico for tesofensine in obesity

      Saniona (SANION.ST), a clinical stage biotech company focused on eating disorders and CNS, today announced that its partner Medix has submitted a new drug application to the Mexican food and drug administration (Comisión Federal para la Protección contra Riesgos Sanitarios, COFEPRIS) for approval of tesofensine for the treatment of patients with obesity. Saniona’s priority is to develop and gain market approval for Tesomet in the U.S. and Europe for Prader-Willi syndrome (PWS) and hypothalamic obesity, two rare eating disorders.

    • Did Business Growth Power Saniona's (STO:SANION) Share Price Gain of 213%?
      Simply Wall St.

      Did Business Growth Power Saniona's (STO:SANION) Share Price Gain of 213%?

      Saniona AB (publ) (STO:SANION) shareholders have seen the share price descend 10% over the month. But that scarcely...

    • GlobeNewswire

      Saniona AB’s Nomination Committee for the Annual General Meeting 2020

      The Annual General Meeting on May 29, 2019, resolved that a Nomination Committee shall be appointed before coming election and remuneration. The Nomination Committee shall comprise three members, which should be representative for the two largest shareholders as of last September, together with the Chairman of the Board of Directors. On September 30, 2019, the two largest shareholders, which desired to appoint a representative to the Nomination Committee, were Jørgen Drejer and Thomas Feldthus.

    • GlobeNewswire

      Saniona publishes its interim report for the third quarter 2019

      PRESS RELEASE November 13, 2019 Financial highlights Jan – Sep 2019 (Jan – Sep 2018) Net revenues were SEK 2.7 M (52.7 M)EBIT was SEK -75.8 M (-19.9 M)Net.

    • GlobeNewswire

      Saniona completes patient recruitment in Phase 2a hypothalamic obesity study

      Saniona (SANION.ST), a clinical stage biotech company focused on eating disorders and CNS, today announces that it has recruited the last patient in the Phase 2a clinical study for Tesomet in hypothalamic obesity. Saniona expects to report top line results from the double-blind part of the study in Q2 2020. “Following the positive Phase 2a data recently reported in Prader-Willi syndrome, we are pleased with the Phase 2a progress in our second rare eating disorder, hypothalamic obesity.

    • Before You Buy Saniona AB (publ) (STO:SANION), Consider Its Volatility
      Simply Wall St.

      Before You Buy Saniona AB (publ) (STO:SANION), Consider Its Volatility

      If you're interested in Saniona AB (publ) (STO:SANION), then you might want to consider its beta (a measure of share...